Implications for insurers Insurers should consider the impact of AOMs across their business: Assess how AOMs may impact protection, morbidity, and longevity experience Review trend assumptions to identify whether changes are needed Establish processes to keep on top of this fast-moving space Consider new lapse risks Assess how AOMs might affect underwriting and claims Insured impacts and reviewing trend assumptions Insurers should consider adjustments to their specific mortality and morbidity improvement assumptions to reflect AOMs
This has led to the availability of medications specifically studied and prescribed for chronic weight management, alongside earlier options that remain clinically relevant in selected individuals
Our findings show that it is not enough to look only at genes, study co-author Elisheva Abberbock, also of Bar-Ilan University, said in a statement
Obesity in 2010: the future of obesity medicine: where do we go from here
MARKET TRENDS IN GLP-1 USAGE Recent market data suggest that around 5% of US adults (approximately 12.5 million people) have used or are currently using GLP-1s for weight loss alone.3 This is higher than the 7.4 million4 people (both adults and children) using insulin and equal to the 5% who have used or are currently using GLP-1s solely to treat a chronic condition such as diabetes or heart disease approximately 3% are using GLP-1s to both treat a chronic condition and to lose weight
Failing to follow product-specific temperature instructions before injection can increase discomfort
.jpg)
